Founders’ Story: VitalTrax

Zikria Syed is the CEO and co-founder of VitalTrax. He talks about why he and co-founder Todd Kueny started their business to make clinical trials more efficient.







Why did you start this company?

“My co-founder Todd Kueny and I have been working in the pharmaceutical industry for over 10 years. We saw firsthand how inefficient the clinical trials process is and wanted to improve it. Clinical trials are necessary for bringing new treatments to market so improving the clinical trials process really helps a lot of people live longer and better lives. Todd’s grandfather has Alzheimer’s and it is one of the many diseases without a treatment so this is also personal.”

What specific need/problem are you seeking to address in healthcare?

“Over 80 percent of clinical trials today are delayed or outright fail due to lack of patient enrollment. We think this is a problem that can be solved by using technology.”

What does your product do? How does it work?

“Our PatientWing solution makes it easy for patients to find and enroll in clinical trials. It also gives research sites and sponsors the tools to list their trials, reach & enroll patients and engage with patients in trials. It does for clinical trials what OpenTable does for restaurants.”

Is this your first healthcare startup? What’s your background in healthcare?

“It is my third startup in pharma. My last company, NextDocs, created document management solutions for the pharma industry. Prior to that, I worked at Microsoft.”

What is your company’s business model?

“PatientWing is always free for patients. Research sites and pharmaceutical companies pay us to recruit patients into clinical trials.”

Who is your customer? How do you generate revenue?

“Research sites and pharmaceutical companies are our clients. They pay us for listing and promoting their trials and enrolling patients. We offer a subscription service as well as per patient enrollment services.”

Do you have clinical validation for your product?

“Yes, our product is successfully used by many research sites and pharmaceutical companies.”